AxoGen, Inc. Q4 FY2025 earnings call

• Strategic plan: Covered growth target, market development in various procedures, commercial expansion of infrastructure and sales force. High potential account strategy with 61% of 2025 revenue growth from them. Surgeon education exceeded targets in 2025. Achieved FDA approval of Avance, with medical societies endorsing nerve allograft as standard of care. R&D focused on nerve coaptation, non-transected and chronic injuries, and therapeutic reconstruction technologies.

In 2025, Q4 revenue was $59.9 million, up 21.3% year-over-year with double-digit growth across all 3 target markets. Full year revenue increased 20.2% to $225.2 million. Adjusted EBITDA grew 41% to $27.9 million. Gross profit for the fourth quarter was $44.4 million, with a gross margin of 74.1%, and full year gross profit was $167.4 million with a gross margin of 74.3%. Avance Nerve Graft is the primary growth driver. In extremities, there's solid growth in traumatic and chronic procedures. Oral maxillofacial and head and neck had high double-digit growth. Breast is a fast-growing opportunity with accelerating adoption. Prostate had over 100 procedures completed across 10 clinical sites in 2025.

Full year 2026 revenue growth expected to be at least 18% (total revenue of at least $265.7 million). Gross margin range for 2026 is 74% to 76%. Anticipate being free cash flow positive in 2026. Higher cash burn expected in the first quarter. Plan to improve gross margin in 2027 through continuous improvement programs and economies of scale.

Q: On the 2026 guidance, how conservative is it and what are the key assumptions?

A: Characterized as prudent, building on a larger base, commercial customer creation models are elastic but need to be managed quarter-to-quarter.

Q: What's the reaction from physicians and payers regarding the BLA?

A: Physician reception varied, BLA allows reaffirming trust; payers have a formal process, no prediction on timing but expect responses by 2028.

Q: Why is the sales force addition number appropriate, especially in segments like extremities?

A: Long way from full coverage in segments such as extremities and breast, incremental growth is planned.

Q: Talk about the cadence of gross margin and clinical evidence for different indications?

A: Q2 sees pressure from Avance Biologic product, clinical evidence varies by indication, some require randomized trials, some controlled studies.

Q: Impact of BLA on growth and high potential accounts?

A: Growth is implicit in guidance, high potential account universe is expected to grow as target indications expand.